Repligen Corporation
NasdaqGS:RGEN Stok Raporu
Repligen Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6 Repligen yıllık ortalama 15.9% oranında kazançlarını artırırken, Life Sciences sektöründe kazançlar growing at 11.7% annual. Gelirler yılda ortalama 20% oranında büyüyor .
Anahtar bilgiler Life Sciences Sektör Büyümesi 21.5% Gelir büyüme oranı 20.0% Özkaynak getirisi -0.1% Net Marj -0.3% Sonraki Kazanç Güncellemesi 12 Nov 2024
Yakın geçmiş performans güncellemeleri
Repligen Corporation to Report Q3, 2024 Results on Nov 12, 2024 Oct 31
Second quarter 2024 earnings: EPS misses analyst expectations Jul 31
Repligen Corporation to Report Q2, 2024 Results on Jul 30, 2024 Jul 16
First quarter 2024 earnings: EPS misses analyst expectations May 01
Repligen Corporation to Report Q1, 2024 Results on May 01, 2024 Apr 19
Repligen Corporation to Report Q4, 2023 Results on Feb 21, 2024 Feb 08
Tüm güncellemeleri göster
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects Nov 12
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet Nov 08
Repligen Corporation to Report Q3, 2024 Results on Nov 12, 2024 Oct 31
Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)? Oct 14
Executive Chair recently sold US$1.8m worth of stock Sep 15
Executive Chair notifies of intention to sell stock Sep 12
Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price Sep 08
Insufficient new directors Sep 05
Now 25% undervalued after recent price drop Sep 03
Now 22% undervalued after recent price drop Aug 16
Insider notifies of intention to sell stock Aug 05
Insider recently sold US$740k worth of stock Aug 04
Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024 Aug 01
Second quarter 2024 earnings: EPS misses analyst expectations Jul 31
Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable Jul 31
Repligen Corporation (NasdaqGS:RGEN) entered into a definitive agreement to acquire Tantti Laboratory Inc. Jul 30
Now 20% undervalued after recent price drop Jul 30
Repligen Corporation to Report Q2, 2024 Results on Jul 30, 2024 Jul 16
We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt Jul 15
Repligen: Strong Filtration Growth, Offset By Other Challenges Jul 13
Now 28% undervalued after recent price drop Jul 01
Now 20% undervalued after recent price drop Jun 27
Repligen Corporation Announces CEO Changes, Effective September 1, 2024 Jun 16 Repligen Corporation Announces Management Changes, Effective September 1, 2024
Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge Jun 14
Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)? Jun 10
Now 20% undervalued after recent price drop Jun 07
Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing Jun 05
Repligen Stock: Still Quite Overvalued May 30
CEO & Director recently sold US$3.4m worth of stock May 24
CEO & Director notifies of intention to sell stock May 23
Consensus EPS estimates increase by 10% May 08
Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models May 03
Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024 May 03
New minor risk - Earnings quality May 01
First quarter 2024 earnings: EPS misses analyst expectations May 01
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN) Apr 30
Repligen Corporation to Report Q1, 2024 Results on May 01, 2024 Apr 19
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet Apr 15
Repligen Corporation, Annual General Meeting, May 16, 2024 Apr 02
Repligen Corporation Appoints Maggie A. Pax as Board of Directors Mar 19
CEO & Director recently sold US$3.3m worth of stock Mar 14
CEO & Director notifies of intention to sell stock Mar 11
Consensus EPS estimates fall by 45% Feb 29
Chief Operating Officer recently sold US$680k worth of stock Feb 28
Chief Operating Officer notifies of intention to sell stock Feb 26
Price target increased by 8.2% to US$205 Feb 22
Repligen Corporation Provides Earnings Guidance for the Year 2024 Feb 22
At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely? Feb 13
Repligen Corporation to Report Q4, 2023 Results on Feb 21, 2024 Feb 08
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN) Jan 08
Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price Dec 19 Repligen Corporation announced that it has received $290.1 million in funding Dec 16
Repligen Corporation announced that it expects to receive $290.1 million in funding Dec 08
Repligen Corporation announced that it expects to receive $290.1 million in funding Dec 07
Insider recently sold US$557k worth of stock Nov 15
Consensus EPS estimates increase by 16% Nov 07
Repligen Corporation Launches TangenX®? SC as First-To-Market Holder-Free Self-Contained TFF Device Nov 03
Price target decreased by 7.6% to US$179 Nov 01
Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2023 Nov 01
What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate? Nov 01
Third quarter 2023 earnings: EPS exceeds analyst expectations Oct 31
Investor sentiment deteriorates as stock falls 16% Oct 26
Repligen Corporation to Report Q3, 2023 Results on Oct 31, 2023 Oct 18
Is Repligen (NASDAQ:RGEN) Using Too Much Debt? Oct 17
Repligen Corporation Appoints Olivier Loeillot as President and Chief Commercial Officer Oct 05
Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation? Sep 29
Repligen Corporation (NasdaqGS:RGEN) entered into a definitive agreement to acquire Metenova AB. Sep 27
Now 23% undervalued Sep 21 Repligen Corporation Appoints Jason K. Garland as Chief Financial Officer Effective September 25, 2023 Sep 13
Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification Aug 18
Now 20% undervalued Aug 18
Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade Aug 09
Consensus revenue estimates fall by 11% Aug 09
Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2023 Aug 03
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 02
Investor sentiment improves as stock rises 17% Jul 21
Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet? Jul 17
Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)? Jul 03
With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case Jun 19
Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN) May 23
Insider recently bought US$238k worth of stock May 10
Consensus EPS estimates fall by 16% May 09
Repligen nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi NasdaqGS:RGEN Gelir, gider ve kazançlar (USD Millions ) Tarih Gelir Kazançlar G+A Giderleri Ar-Ge Giderleri 30 Jun 24 602 -2 237 42 31 Mar 24 607 15 222 42 31 Dec 23 639 42 216 43 30 Sep 23 670 116 210 44 30 Jun 23 729 138 212 43 31 Mar 23 778 168 218 44 31 Dec 22 802 186 216 44 30 Sep 22 801 166 210 42 30 Jun 22 779 159 204 41 31 Mar 22 734 146 194 39 31 Dec 21 671 128 184 34 30 Sep 21 593 119 164 32 30 Jun 21 509 100 145 27 31 Mar 21 433 80 127 23 31 Dec 20 366 60 116 20 30 Sep 20 327 44 112 19 30 Jun 20 302 31 107 20 31 Mar 20 286 23 100 21 31 Dec 19 270 21 96 19 30 Sep 19 253 23 81 17 30 Jun 19 233 27 72 16 31 Mar 19 210 21 69 16 31 Dec 18 194 17 66 16 30 Sep 18 184 23 64 16 30 Jun 18 171 23 64 14 31 Mar 18 155 29 58 10 31 Dec 17 141 28 52 9 30 Sep 17 125 21 43 8 30 Jun 17 113 18 34 8 31 Mar 17 110 13 31 8 31 Dec 16 105 12 31 7 30 Sep 16 100 7 27 7 30 Jun 16 96 8 28 6 31 Mar 16 88 8 25 6 31 Dec 15 84 9 25 6 30 Sep 15 78 9 23 6 30 Jun 15 74 8 21 6 31 Mar 15 68 7 19 6 31 Dec 14 64 8 16 6 30 Sep 14 63 12 15 6 30 Jun 14 66 16 14 5 31 Mar 14 68 18 13 6 31 Dec 13 68 16 13 7
Kaliteli Kazançlar: RGEN şu anda kârlı değil.
Büyüyen Kar Marjı: RGEN şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: RGEN kârlı değildir, ancak son 5 yılda zararlarını yılda 15.9% oranında azaltmıştır.
Büyüme Hızlandırma: RGEN 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: RGEN kârlı olmadığından, geçmiş yıl kazanç büyümesinin Life Sciences sektörüyle ( -4.7% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: RGEN hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi 'ne ( -0.096% ) sahiptir.
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
